Skip to content
Screener

Roivant Sciences ROIV Q3 2025 earnings

Reported February 6, 2026 · Before market open

Revenue$2.0MMiss by $3.1M
EPS-$0.24Beat by $0.06
Revenue estimate$5.1M
EPS estimate-$0.30

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$3.4M
EPS estimate-$0.41

Financials

Q3 2025

Income statement

See full
Revenue$2.0M-77.8%
Operating income-$339.2M-23.6%
Net income-$265.9M-257%
EPS (diluted)-$0.38-265%

Balance sheet

See full
Cash & equivalents$91.9M-7.2%
Total debt$108.9M+8.6%
Total equity$4.3B-17.7%
Total assets$5.2B-9.8%

Cash flow

See full
Operating cash flow-$196.5M+5.2%
Free cash flow-$191.5M+8.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$15.09B+75.3%
Enterprise value$15.11B+75.4%
P/S1,133.9×+852×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-5,761.5%-28,390pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0×0.0×
Current ratio30.7×-7.2×

Segments

By segment

See full
Reportable Segment$2.0M-77.8%

FAQ

When did Roivant Sciences report Q3 2025 earnings?
Roivant Sciences (ROIV) reported Q3 2025 earnings on February 6, 2026 before market open.
What were Roivant Sciences's Q3 2025 revenue and EPS?
Roivant Sciences reported revenue of $2.0M and eps of $-0.24 for Q3 2025.
Did Roivant Sciences beat estimates in Q3 2025?
Revenue missed the consensus estimate of $5.1M by $3.1M. EPS beat the consensus estimate of $-0.30 by $0.06.
How did Roivant Sciences's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 77.8% from $9.0M a year earlier and eps declined 84.6% from $-0.13.
Where can I find Roivant Sciences's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001635088-26-000009) and the 10-Q periodic report (0001635088-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.